How to appeal a Wegovy insurance denial: the complete 2026 guide

TLDR. Insurance denies Wegovy on the first pass roughly 40 to 60 percent of the time. The odds flip sharply on appeal: 60 to 75 percent of level-1 internal appeals succeed when the letter directly rebuts the specific denial reason. The critical variable is identifying which of the six common denial reasons your plan cited, then addressing it with the documentation the plan actually requires. This guide covers each reason, the evidence to attach, and the timeline your appeal must clear.

When an insurance plan denies a Wegovy prior authorization, the denial letter includes a stated reason. That reason is the only thing that matters for the appeal. Plans that deny "medical necessity" without specifics lose appeals at high rates because they cannot articulate a clinical basis that holds up to external review. Plans that cite a specific structural reason (step therapy, BMI calculation, missing comorbidity documentation) can be beaten by directly rebutting that reason with documentation.

Most appeals fail because the letter ignores the stated denial reason and re-argues the general case for Wegovy. Payers see dozens of those letters every week. The ones that succeed address the exact language in the denial letter.

Step 1: Find the denial reason in the letter

Your plan is required to issue a written denial letter that states the specific clinical or administrative reason for the denial. This arrives as a letter separate from your Explanation of Benefits (EOB), or as an Adverse Benefit Determination notice for employer-sponsored plans governed by ERISA.

The denial reason is usually in the third or fourth paragraph. Look for language like "step therapy criteria not met," "BMI does not meet threshold," "lacks documentation of lifestyle intervention," or "not medically necessary." That phrase is the key. Everything else is administrative boilerplate.

If the denial letter does not state a specific clinical reason, that absence is itself an appealable procedural defect. Note it and flag it in your appeal letter.

Step 2: Match your denial to one of six categories

Across 20 major US health plans, Wegovy denials fall into six categories. Each has a different rebuttal strategy and a different documentation requirement.

1. Step therapy requirement not met

The most common type. The plan requires a documented trial of a lower-cost agent (phentermine, orlistat, or a structured-diet-program enrollment) before approving Wegovy.

What wins: prior trial of a step-therapy agent at any point in the patient's history (not only the past 12 months), a documented contraindication to phentermine (cardiovascular disease is the standard one) or orlistat (malabsorption), or documented intolerance at any time. If none of those exist, a 4 to 12 week documented phentermine trial followed by a re-submission is often faster than appealing.

Our step-therapy appeal letter templates address this reason for each of the 20 major plans.

2. BMI below the qualifying threshold

The plan calculated BMI below 30, or below 27 if the comorbidity pathway was used. This often traces to a stale BMI entry in the submitted EMR records.

What wins: current BMI measurement dated within 30 days, with the clinical setting documented. If the BMI is genuinely below threshold, the obesity indication is not the right path. Pivot to the cardiovascular indication (SELECT trial) if the patient has established cardiovascular disease, or the OSA indication (SURMOUNT-OSA) if sleep apnea is documented.

3. Insufficient comorbidity documentation

Used for BMI 27 to 29.9 patients, where Wegovy's labeling requires a weight-related comorbidity. The plan does not see the comorbidity in the records submitted.

What wins: the comorbidity ICD-10 from any prior visit. Qualifying comorbidities include T2D (E11.x), hypertension (I10), dyslipidemia (E78.x), OSA (G47.33), NAFLD (K76.0), PCOS (E28.2) and GERD (K21.x). Attach the visit note or problem-list excerpt showing the ICD-10 code and date.

4. Insufficient documentation of lifestyle intervention

The plan requires six months of documented dietary or behavioral intervention before approving a GLP-1.

What wins: the bar is documentation, not clinical outcome. Self-reported diet attempts, gym membership, prior structured-program participation (Weight Watchers, Noom, hospital obesity program) or prior anti-obesity medication trials all qualify. Attach anything with dates that shows six months of effort.

5. Formulary exclusion (plan excludes obesity drugs)

The hardest denial to reverse. Some employer-sponsored plans carve out anti-obesity drugs entirely.

What wins: a non-obesity indication, if the patient qualifies. Wegovy is FDA-approved for cardiovascular event reduction (SELECT trial, established CVD without diabetes) independently of the obesity indication. Zepbound carries an FDA-approved OSA indication (SURMOUNT-OSA). Ozempic and Mounjaro are on most T2D formularies. If the patient qualifies for any of these, pivot the entire PA to the non-obesity indication.

If the plan has no covered pathway at all, cash-pay routes are the realistic alternative. NovoCare direct at $349 per month provides branded Wegovy without prior authorization. See our Wegovy cost without insurance guide for the current cash-pay landscape.

6. Boilerplate "not medically necessary"

The easiest denial to beat on appeal. When a plan returns a generic medical-necessity denial without specifying a clinical objection, the appeal letter presents patient-specific clinical evidence and explicitly asks the plan to articulate its clinical basis for any continued denial.

Why this works: plans must provide a specific clinical rationale at second-level review, and that rationale must hold up against the FDA labeling and the registration trial evidence. Plans that issue boilerplate denials often approve at first-level appeal when the letter is specific and well-documented.

Our medical-necessity appeal letter templates address this reason for all 20 major plans.

Step 3: Build the documentation package

The appeal goes to a different clinician at the plan than the one who issued the denial. They read the denial reason and the clinical record you attached. The appeal letter is the argument; the documentation is the evidence. They need both.

For most Wegovy appeals, the package includes:

• Current BMI measurement with date and clinical setting
• Comorbidity ICD-10 codes with the originating visit dates
• Evidence of prior weight-management attempts with dates
• Treating clinician's notes on medical necessity
• The registration trial citation for the relevant indication: STEP-1 (obesity), SELECT (established CVD), or SURMOUNT-OSA (OSA)

For step-therapy denials: prior phentermine trial records, contraindication documentation, or any prior anti-obesity medication trial. The date range is usually the patient's full history, not only the past 12 months.

Step 4: Know your timeline

Missing the appeal window is the most common procedural failure. The clock starts from the date on the denial letter, not the date you received it.

• Standard commercial plans (ERISA-governed): 180 days to file a level-1 internal appeal.
• UnitedHealthcare: 65 days for many plan types. Read your plan documents before assuming 180 days.
• Medicare Advantage: 60 days to file a coverage determination appeal.
• State-regulated individual and small-group plans: typically 60 to 180 days. Check your state insurance department for your plan type.

Calendar the deadline the day you receive the denial letter. If you are close to expiration, file a basic appeal with partial documentation and supplement after filing.

Step 5: File through your clinician

The appeal must be signed by the treating clinician (MD, DO, NP or PA with prescribing authority). Most plans accept submissions via fax, secure portal, or certified mail. The submission address for the appeals department is on the denial letter.

The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), in effect January 2026, requires plans to respond to standard prior authorization requests within 7 calendar days and urgent requests within 72 hours. This applies to Medicare Advantage, Medicaid managed care and federal marketplace plans. Commercial employer-sponsored plans have ERISA deadlines (30 days standard, 72 hours urgent).

For plan-specific submission instructions across all 20 major plans, the appeal letter library includes the submission method and contact address for each plan-denial reason combination.

What happens after you file

Level-1 internal appeal. A different clinician at the plan reviews your file. Most Wegovy appeals that succeed do so here. If the letter directly addresses the denial reason with patient-specific evidence, expect a decision in 30 days standard, 72 hours urgent.

Level-2 internal appeal (if level-1 is upheld). Reviewed by a panel that typically includes an external clinician. At this stage the plan is defending a specific clinical position, which is harder when the original denial was boilerplate.

External independent review (if both internal levels fail). A state-regulated IRO (independent review organization) reviews the case against the FDA labeling and registration trial evidence. Plans must comply with external review decisions under the ACA and ERISA. Success rates exceed 80 percent at this stage for Wegovy appeals where the patient meets the FDA-labeled criteria.

When cash-pay is faster than appealing

If the plan has a formulary exclusion with no covered non-obesity indication, or if the appeal timeline would leave the patient without medication for more than four weeks, cash-pay is often the faster path. NovoCare direct at $349 per month provides branded Wegovy without prior authorization. Compounded routes at $99 to $199 still exist for some patients, though the regulatory path is narrowing.

For the full comparison of cash-pay routes including NovoCare and telehealth programs, see our Wegovy cost without insurance guide. For alternatives if Wegovy is out of reach entirely, see our cheapest Wegovy alternative guide.

Frequently asked questions

What is the success rate for Wegovy insurance appeals?

Level-1 internal appeals succeed 60 to 75 percent of the time when the letter directly rebuts the specific denial reason with patient documentation. The rate drops for generic letters that re-argue the general case for Wegovy without addressing the stated denial code. External review succeeds over 80 percent of the time for patients who meet FDA-labeled criteria.

How long does a Wegovy insurance appeal take?

Level-1 internal appeals: up to 30 days standard, 72 hours urgent. Level-2 internal: similar. External review: typically 30 to 45 days depending on state rules. NovoCare at $349 per month can bridge the gap without prior authorization while the appeal processes.

Who writes the Wegovy appeal letter?

The treating clinician signs the appeal (MD, DO, NP or PA with prescribing authority). Patients can draft it using our templates, but the clinician must review, fill in patient-specific clinical findings and sign. A letter identifying specific ICD-10 codes, trial citations and plan-criteria references, signed by the prescriber, is substantially more effective than a patient-authored letter.

What if my plan excludes all obesity drugs on the formulary?

The appeal cannot win on the obesity indication if the exclusion is a plan-level carve-out. Options are: (1) pivot to a covered non-obesity indication (cardiovascular for Wegovy under SELECT, OSA for Zepbound under SURMOUNT-OSA, T2D for Ozempic or Mounjaro); (2) wait for open enrollment and select a plan that covers obesity drugs; or (3) use cash-pay routes. Plans that exclude anti-obesity drugs entirely are a shrinking minority as state parity laws expand.

Is the Medicare appeal process different?

Medicare Part D does not cover Wegovy for the obesity indication under the 2003 Medicare Modernization Act, though the Inflation Reduction Act is expanding coverage over time. The cardiovascular indication (established CVD plus BMI 27 or higher without diabetes, as studied in SELECT) is covered on many Medicare Part D and Medicare Advantage plans because it bypasses the obesity-indication exclusion. The Medicare Advantage appeal window is 60 days, shorter than most commercial plans.